Two Sigma Advisers
CRNX icon

Two Sigma Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

Two Sigma Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,300
Closed -$2.22M – 2402
2025
Q3 		$2.22M Sell
53,300
-14,000
-21% -$448K ﹤0.01% 1102
2025
Q2 		$1.94M Buy
67,300
+61,000
+968% +$1.88M ﹤0.01% 1138
2025
Q1 		$211K Sell
6,300
-1,800
-22% -$67.2K ﹤0.01% 2116
2024
Q4 		$414K Sell
8,100
-14,300
-64% -$800K ﹤0.01% 1846
2024
Q3 		$1.14M Sell
22,400
-11,200
-33% -$578K ﹤0.01% 1355
2024
Q2 		$1.5M Buy
33,600
+1,800
+6% +$83.1K ﹤0.01% 1353
2024
Q1 		$1.49M Sell
31,800
-7,000
-18% -$274K ﹤0.01% 1374
2023
Q4 		$1.38M Sell
38,800
-46,100
-54% -$1.41M ﹤0.01% 1473
2023
Q3 		$2.52M Buy
84,900
+22,500
+36% +$464K 0.01% 1070
2023
Q2 		$1.12M Buy
62,400
+2,100
+3% +$41.9K ﹤0.01% 1488
2023
Q1 		$968K Sell
60,300
-39,100
-39% -$724K ﹤0.01% 1647
2022
Q4 		$1.82M Sell
99,400
-29,100
-23% -$513K 0.01% 1292
2022
Q3 		$2.52M Sell
128,500
-1,300
-1% -$26.5K 0.01% 1056
2022
Q2 		$2.42M Sell
129,800
-11,500
-8% -$230K 0.01% 1113
2022
Q1 		$3.1M Sell
141,300
-11,100
-7% -$225K 0.01% 1025
2021
Q4 		$4.33M Buy
152,400
+12,600
+9% +$311K 0.01% 831
2021
Q3 		$2.94M Buy
139,800
+54,800
+64% +$1.15M 0.01% 1046
2021
Q2 		$1.6M Buy
85,000
+50,700
+148% +$891K ﹤0.01% 1412
2021
Q1 		$524K Buy
34,300
+11,700
+52% +$181K ﹤0.01% 2006
2020
Q4 		$319K Buy
22,600
+10,300
+84% +$143K ﹤0.01% 2024
2020
Q3 		$193K Buy
12,300
+500
+4% +$7.64K ﹤0.01% 2163
2020
Q2 		$207K Buy
+11,800
New +$201K ﹤0.01% 2235

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Two Sigma Advisers's CRNX Position: Q4 2025 in Review

Two Sigma Advisers sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 53,300 shares — an estimated $2.22M sold.

Two Sigma Advisers first reported a position in CRNX in Q2 2020 and held it in 22 quarters. The position peaked at $4.33M in Q4 2021. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Two Sigma Advisers reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 53,300 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $2.22M.
  • Two Sigma Advisers first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 22 quarters.
  • Two Sigma Advisers's Crinetics Pharmaceuticals position peaked at $4.33M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.